临终医保受益者无创与有创机械通气使用趋势
与2000年相比,2017年NIV使用调整比值比(AOR)为11.84(95%CI 11.11-12.61),使用率从0.8%升至7.1%;IMV使用AOR为1.63(95%CI 1.59-1.66),使用率从15.0%升至18.2%。亚组中,心衰和COPD患者NIV使用大幅增加而IMV趋于稳定,癌症和痴呆患者NIV亦显著增加。使用NIV者院内死亡率(50.3% vs 76.7%)和生命最后3天临终关怀入组率(57.7% vs 63.0%)低于IMV者,而临终关怀入组率更高(41.3% vs 20.0%)。
要点
- 2000至2017年,临终前30天内住院的医保受益者中NIV使用率从0.8%升至7.1%(AOR 11.84,95%CI 11.11-12.61)。
- 同期IMV使用率从15.0%升至18.2%(AOR 1.63,95%CI 1.59-1.66),增幅远小于NIV。
- 心衰患者NIV使用率从1.4%升至14.2%(AOR 14.14,95%CI 11.77-16.98),IMV无显著变化(AOR 1.07,95%CI 0.95-1.19)。
- COPD患者NIV使用率从2.7%升至14.5%(AOR 8.22,95%CI 6.42-10.52),IMV无显著变化(AOR 1.03,95%CI 0.88-1.21)。
- 使用NIV者院内死亡率50.3%(95%CI 49.3%-51.3%),低于IMV者的76.7%(95%CI 75.9%-77.5%)。
适用人群与场景
- 20%随机抽样的Medicare按服务收费受益者,在生命最后30天内有过急性住院并死亡,死亡时间在2000年1月1日至2017年12月31日之间。
- 亚组包括以COPD、充血性心力衰竭、癌症和痴呆为主要入院诊断编码的受益者。
诊断标准与关键阈值
- 使用经审查验证的ICD-9-CM或ICD-10-CM操作编码识别NIV、IMV、两者兼有或均无。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 2000年NIV使用率0.8%,2005年2.0%(AOR 2.63,95%CI 2.46-2.82),2017年7.1%(AOR 11.84,95%CI 11.11-12.61)。
- 2000年IMV使用率15.0%,2005年15.2%(AOR 1.04,95%CI 1.02-1.06),2017年18.2%(AOR 1.63,95%CI 1.59-1.66)。
- 心衰亚组2017年vs 2000年:NIV使用率1.4% vs 14.2%(AOR 14.14,95%CI 11.77-16.98);IMV使用率11.1% vs 7.8%(AOR 1.07,95%CI 0.95-1.19)。
- COPD亚组2017年vs 2000年:NIV使用率2.7% vs 14.5%(AOR 8.22,95%CI 6.42-10.52);IMV使用率17.4% vs 13.2%(AOR 1.03,95%CI 0.88-1.21)。
- 癌症亚组NIV使用率0.4% vs 3.5%(AOR 10.82,95%CI 8.16-14.34),IMV使用率6.2% vs 7.6%(AOR 1.40,95%CI 1.26-1.55)。
- 痴呆亚组NIV使用率0.6% vs 5.2%(AOR 9.62,95%CI 7.61-12.15),IMV使用率5.7% vs 6.2%(AOR 1.28,95%CI 1.17-1.41)。
- NIV vs IMV使用者:院内死亡率50.3%(95%CI 49.3%-51.3%)vs 76.7%(95%CI 75.9%-77.5%);临终关怀入组率41.3%(95%CI 40.4%-42.3%)vs 20.0%(95%CI 19.2%-20.7%);生命最后3天临终关怀入组率57.7%(95%CI 56.2%-59.3%)vs 63.0%(95%CI 60.9%-65.1%)。
证据类型、等级与局限
- 证据类型:基于人群的回顾性队列研究(使用行政索赔数据)。
- 局限:原文未述局限性。
对床旁实践的改变
- 对于临终前30天内住院的COPD、心衰、癌症或痴呆患者,NIV使用在2000至2017年间大幅增加,提示临床中可能更多以NIV作为避免IMV的选择。
- 使用NIV者院内死亡率低于IMV者(50.3% vs 76.7%),临终关怀入组率更高(41.3% vs 20.0%),但该比较为观察性数据。
- 原文建议开展试验评估NIV的结局,以指导临床医生与患者及其医疗代理人关于该治疗目标的讨论。
指南或共识出处
- 来源:JAMA Intern Med;研究论文,原文未提供指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: End-of-life care is costly, and decedents often experience overtreatment or low-quality care. Noninvasive ventilation (NIV) may be a palliative approach to avoid invasive mechanical ventilation (IMV) among select patients who are hospitalized at the end of life.
OBJECTIVE: To examine the trends in NIV and IMV use among decedents with a hospitalization in the last 30 days of life.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used a 20% random sample of Medicare fee-for-service beneficiaries who had an acute care hospitalization in the last 30 days of life and died between January 1, 2000, and December 31, 2017. Sociodemographic, diagnosis, and comorbidity data were obtained from Medicare claims data. Data analysis was performed from September 2019 to July 2020.
EXPOSURES: Use of NIV or IMV.
MAIN OUTCOMES AND MEASURES: Validated International Classification of Diseases, Ninth Revision, Clinical Modification or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification procedure codes were reviewed to identify use of NIV, IMV, both NIV and IMV, or none. Four subcohorts of Medicare beneficiaries were identified using primary admitting diagnosis codes (chronic obstructive pulmonary disease [COPD], congested heart failure [CHF], cancer, and dementia). Measures of end-of-life care included in-hospital death (acute care setting), hospice enrollment at death, and hospice enrollment in the last 3 days of life. Random-effects logistic regression examined NIV and IMV use adjusted for sociodemographic characteristics, admitting diagnosis, and comorbidities.
RESULTS: A total of 2 470 435 Medicare beneficiaries (1 353 798 women [54.8%]; mean [SD] age, 82.2 [8.2] years) were hospitalized within 30 days of death. Compared with 2000, the adjusted odds ratio (AOR) for the increase in NIV use was 2.63 (95% CI, 2.46-2.82; % receipt: 0.8% vs 2.0%) for 2005 and 11.84 (95% CI, 11.11-12.61; % receipt: 0.8% vs 7.1%) for 2017. Compared with 2000, the AOR for the increase in IMV use was 1.04 (95% CI, 1.02-1.06; % receipt: 15.0% vs 15.2%) for 2005 and 1.63 (95% CI, 1.59-1.66; % receipt: 15.0% vs 18.2%) for 2017. In subanalyses comparing 2017 with 2000, similar trends found increased NIV among patients with CHF (% receipt: 1.4% vs 14.2%; AOR, 14.14 [95% CI, 11.77-16.98]) and COPD (% receipt: 2.7% vs 14.5%; AOR, 8.22 [95% CI, 6.42-10.52]), with reciprocal stabilization in IMV use among patients with CHF (% receipt: 11.1% vs 7.8%; AOR, 1.07 [95% CI, 0.95-1.19]) and COPD (% receipt: 17.4% vs 13.2%; AOR, 1.03 [95% CI, 0.88-1.21]). The AOR for increased NIV use was 10.82 (95% CI, 8.16-14.34; % receipt: 0.4% vs 3.5%) among decedents with cancer and 9.62 (95% CI, 7.61-12.15; % receipt: 0.6% vs 5.2%) among decedents with dementia. The AOR for increased IMV use was 1.40 (95% CI, 1.26-1.55; % receipt: 6.2% vs 7.6%) among decedents with cancer and 1.28 (95% CI, 1.17-1.41; % receipt: 5.7% vs 6.2%) among decedents with dementia. Among decedents with NIV vs IMV use, lower rates of in-hospital death (50.3% [95% CI, 49.3%-51.3%] vs 76.7% [95% CI, 75.9%-77.5%]) and hospice enrollment in the last 3 days of life (57.7% [95% CI, 56.2%-59.3%] vs 63.0% [95% CI, 60.9%-65.1%]) were observed along with higher rates of hospice enrollment (41.3% [95% CI, 40.4%-42.3%] vs 20.0% [95% CI, 19.2%-20.7%]).
CONCLUSIONS AND RELEVANCE: This study found that the use of NIV rapidly increased from 2000 through 2017 among Medicare beneficiaries at the end of life, especially among persons with cancer and dementia. The findings suggest that trials to evaluate the outcomes of NIV are warranted to inform discussions about the goals of this therapy between clinicians and patients and their health care proxies.
参考来源
- Sullivan DR, Kim H, Gozalo PL, et al. Trends in Noninvasive and Invasive Mechanical Ventilation Among Medicare Beneficiaries at the End of Life. JAMA Intern Med. 2021. PMID: 33074320. doi:10.1001/jamainternmed.2020.5640
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。